Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial

Jia-bo WANG; Zhong-xia WANG; Jing JING; Peng ZHAO; Jing-hui DONG; Yong-feng ZHOU; Guang YANG; Ming NIU; Xu ZHAO; Tian-jun JIANG; Jing-feng BI; Zhe XU; Ping ZHANG; Dan WU; Zhao-fang BAI; Yu-ming GUO; Si-miao YU; Yong-qiang SUN; Zi-teng ZHANG; Xiao-yan ZHAN; Peng-yan LI; Jin-biao DING; Peng-fei ZHAO; Xue-ai SONG; Jian-yuan TANG; Dong-chu HE; Zhu CHEN; En-qiang QIN; Rui-lin WANG; Xiao-he XIAO

doi:10.1007/s11655-020-3426-7

Your Location：

Home >

Browse articles >

Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial

Original Article | Updated：2021-08-23

- Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial
- Chinese Journal of Integrative Medicine Vol. 26, Issue 9, Pages: 648-655(2020)
- Affiliations：
  
  1.China Military Institute of Chinese Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing (100039), China
  2.Integrative Medical Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing (100039), China
  3.Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing (100039), China
  4.National Clinical Research Center for Infectious Diseases, Beijing (100039), China
  5.Department of Radiology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing (100039), China
  6.Research Center for Clinical and Translational Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing (100039), China
  7.Sichuan Evidence-Based Medicine Center of Traditional Chinese Medicine Affliated Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu (610075), China
  8.College of Life Science, Beijing University of Chinese Medicine, Beijing (100029), China
  9.Department of Integrated Treatment, General Hospital of Central Theater Command, Wuhan (430070), China
- Author bio：
  
  Prof. QIN En-qiang, E-mail:qeq2004@sina.com
  Prof. WANG Rui-lin, E-mail:wrl7905@163.com;
  Correspondence to: Prof. XIAO Xiao-he, E-mail:pharmacy302xxh@126.com;
- Funds：
- DOI：10.1007/s11655-020-3426-7
  CLC：
- Published：01 September 2020，
  
  Published Online：16 July 2020，
  
  Accepted：26 June 2020
Scan for full text
Jia-bo WANG, Zhong-xia WANG, Jing JING, et al. Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial. [J]. Chinese Journal of Integrative Medicine 26(9):648-655(2020)
DOI：

Jia-bo WANG, Zhong-xia WANG, Jing JING, et al. Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial. [J]. Chinese Journal of Integrative Medicine 26(9):648-655(2020) DOI： 10.1007/s11655-020-3426-7.

摘要

Abstract

Objectives:

To develop a new Chinese medicine (CM)-based drug and to evaluate its safety and effect for suppressing acute respiratory distress syndrome (ARDS) in COVID-19 patients.

Methods:

A putative ARDS-suppressing drug Keguan-1 was first developed and then evaluated by a randomized

controlled two-arm trial. The two arms of the trial consist of a control therapy (alpha interferon inhalation

50 μg twice daily; and lopinavir/ritonavir

400 and 100 mg twice daily

respectively) and a testing therapy (control therapy plus Keguan-1 19.4 g twice daily) by random number table at 1:1 ratio with 24 cases each group. After 2-week treatment

adverse events

time to fever resolution

ARDS development

and lung injury on newly diagnosed COVID-19 patients were assessed.

Results:

An analysis of the data from the first 30 participants showed that the control arm and the testing arm did not exhibit any significant differences in terms of adverse events. Based on this result

the study was expanded to include a total of 48 participants (24 cases each arm). The results show that compared with the control arm

the testing arm exhibited a significant improvement in time to fever resolution (

=0.035)

and a significant reduction in the development of ARDS (

=0.048).

Conclusions:

Keguan-1-based integrative therapy was safe and superior to the standard therapy in suppressing the development of ARDS in COVID-19 patients. (Trial registration No. NCT 04251871 at www.clinicaltrials.gov)

关键词

Keywords

COVID-19SARS-CoV-2acute respiratory distress syndromeChinese medicine

references

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Analysis of Chinese Medical Syndrome Features of Ischemic Stroke Based on Similarity of Symptoms Subgroup

Protective Mechanism of Cordyceps sinensis Treatment on Acute Kidney Injury-Induced Acute Lung Injury through AMPK/mTOR Signaling Pathway

Related Author

No data

Related Institution

Hong Kong Modern Chinese Medicine Research & Development Center

Department of Cardiology,Dongzhimen Hospital, Beijing University of Chinese Medicine

Cardiovascular Disease Center, Xiyuan Hospital, National Clinical Research Center for Chinese Medicine Cardiology,China Academy of Chinese Medical Sciences

Department of Biology, Southern University of Science and Technology

School of Medicine, Southern University of Science and Technology

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰